Literature DB >> 8404170

Pathogenesis of Cheyne-Stokes respiration in patients with congestive heart failure. Relationship to arterial PCO2.

P Hanly1, N Zuberi, R Gray.   

Abstract

In order to determine which patients with congestive heart failure (CHF) develop Cheyne-Stokes respiration (CSR) during sleep, we compared the cardiorespiratory profiles of CHF patients with CSR to those of CHF patients without CSR. Overnight polysomnography and continuous transcutaneous PCO2 (tc PCO2) monitoring, estimation of left ventricular ejection fraction (LVEF), pulmonary function tests, and chest radiograph were performed on 16 consecutive patients with chronic, stable CHF. The tc PCO2 monitor (Kontron 7640) was calibrated so that measurements reflected arterial PCO2 values. A mean value was calculated for wakefulness (W) and total sleep time (TST). Circulation time (CT) from the lung to the carotid body was estimated from the end of an apnea or voluntary breath-hold to the nadir of oxygen desaturation recorded on an ear oximeter. The duration of CSR was expressed as a percent of TST. Nine patients developed CSR during sleep (52.5 +/- 31.6 percent TST) (group 1) and 7 did not (group 2). All patients were male and both groups were a similar age (64 +/- 8 vs 63 +/- 4 years) and weight (body mass index, 28.1 +/- 3.5 vs 25.4 +/- 3.4 kg/m2). There were no significant intergroup differences between LVEF (22 +/- 5.2 vs 24.1 +/- 5.2 percent), CT (19.1 +/- 3.6 vs 15.9 +/- 6.7 s), SaO2 (W) (94 +/- 1.2 vs 92.4 +/- 2.1 percent), and SaO2 (TST) (90.8 +/- 2.7 vs 92.4 +/- 2.1 percent). The tc PCO2 (W) was lower in group 1 (34.4 +/- 3.5 vs 38.1 +/- 1.9 mm Hg), increased during sleep by a similar amount in both groups (1.6 +/- 1.5 vs 2.1 +/- 2.2 mm Hg), and was significantly lower during sleep in group 1 (36.1 +/- 3.4 vs 40.2 +/- 2.2 mm Hg). We conclude that CHF patients with CSR hyperventilate during sleep and wakefulness and that CHF patients with awake hypocapnia are more likely to develop CSR during sleep. These findings indicate that arterial PCO2 is important in determining which CHF patients develop CSR.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8404170     DOI: 10.1378/chest.104.4.1079

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  34 in total

1.  Treatment of central sleep apnoea in congestive heart failure with nasal ventilation.

Authors:  G N Willson; I Wilcox; A J Piper; W E Flynn; R R Grunstein; C E Sullivan
Journal:  Thorax       Date:  1998-10       Impact factor: 9.139

Review 2.  What is central sleep apnea?

Authors:  Atul Malhotra; Robert L Owens
Journal:  Respir Care       Date:  2010-09       Impact factor: 2.258

3.  Ventilatory patterning in a mouse model of stroke.

Authors:  Brian B Koo; Kingman P Strohl; Carl B Gillombardo; Frank J Jacono
Journal:  Respir Physiol Neurobiol       Date:  2010-05-21       Impact factor: 1.931

4.  Impact of sleeping angle on the upper airway and pathogenesis of Cheyne Stokes Respiration.

Authors:  Patrick J Hanly
Journal:  Sleep       Date:  2009-11       Impact factor: 5.849

Review 5.  Pathophysiology and treatment of Cheyne-Stokes respiration.

Authors:  M T Naughton
Journal:  Thorax       Date:  1998-06       Impact factor: 9.139

6.  A cardiovascular-respiratory control system model including state delay with application to congestive heart failure in humans.

Authors:  Jerry J Batzel; Franz Kappel; Susanne Timischl-Teschl
Journal:  J Math Biol       Date:  2004-10-07       Impact factor: 2.259

7.  Ventilatory responses to chemoreflex stimulation are not enhanced by angiotensin II in healthy humans.

Authors:  Adil Z Solaiman; Robert P Feehan; Amy M Chabitnoy; Urs A Leuenberger; Kevin D Monahan
Journal:  Auton Neurosci       Date:  2014-02-08       Impact factor: 3.145

Review 8.  Cheyne-stokes respiration in patients with heart failure.

Authors:  Laila AlDabal; Ahmed S BaHammam
Journal:  Lung       Date:  2009-12-03       Impact factor: 2.584

Review 9.  Sleep: important considerations for the prevention of cardiovascular disease.

Authors:  Michael A Grandner; Pamela Alfonso-Miller; Julio Fernandez-Mendoza; Safal Shetty; Sundeep Shenoy; Daniel Combs
Journal:  Curr Opin Cardiol       Date:  2016-09       Impact factor: 2.161

10.  Dynamic CO2 therapy in periodic breathing: a modeling study to determine optimal timing and dosage regimes.

Authors:  Yoseph Mebrate; Keith Willson; Charlotte H Manisty; Resham Baruah; Jamil Mayet; Alun D Hughes; Kim H Parker; Darrel P Francis
Journal:  J Appl Physiol (1985)       Date:  2009-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.